搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
5 天
Excess body weight linked to increased risk for second primary neoplasm
Among cancer survivors, excess body weight is associated with an increased risk for a second primary malignant neoplasm, ...
18 天
学术动态 | 手机等射频辐射不会导致脑恶性肿瘤发生 一项覆盖28年的 ...
研究结果显示,脑恶性肿瘤(Malignant Neoplasm of the Brain)随着手机使用时间、累计通话时间或累计通话次数的增加, 风险并未明显增加 ;无绳电话的使用与脑胶质瘤、脑膜瘤或听神经瘤的风险 无显著相关性 ...
The American Journal of Managed Care
11 天
Celiac Disease Associated With Varying Risks for Cancers
Celiac disease presents a higher risk for developing malignant neoplasms, including small intestine, lymphoma, and skin ...
3 小时
Foundation Medicine Awarded Contract by the U.S. Department of Veterans Affairs to Provide ...
Foundation Medicine was awarded its 2nd consecutive, 5-year contract by the U.S. Department of Veterans Affairs to provide tumor molecular profiling.
Medscape
4 天
Elinzanetant Shows Significant Improvement in Menopausal Vasomotor and Sleep Symptoms
Targeting two receptors instead of the one targeted by fezolinetant, the new elinzanetant did not show the liver safety ...
The Focus on MSN
7 天
Common product most people have in their bathroom 'probably' causes cancer
Did you know that one common item most people have in their bathroom cupboard right now ‘probably causes cancer’? That item ...
Oncology Nurse Advisor
7 天
Underreporting of Patient-Reported Outcomes Seen in Blood Cancer Trials
Researchers sought to assess the reporting of patient-reported outcomes in associated clinical trial publications.
Medpage Today on MSN
8 天
Long-Term Data Support Non-Hormonal Drug for Hot-Flash Management
CHICAGO -- The non-hormonal drug elinzanetant reduced the frequency of moderate-to-severe hot flashes in postmenopausal women ...
6 天
Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an ...
FIRST COLLABORATIVE EFFORT UNDER NEW AGREEMENT ALLEN, TX / ACCESSWIRE / September 18, 2024 / (OTC PINK:ENZC) ("enzolytics.com ...
Pharmaceutical Technology
15 天
Cetuximab biosimilar by Alkem Laboratories for Pharyngeal Neoplasm: Likelihood of Approval
Cetuximab biosimilar is under clinical development by Alkem Laboratories and currently in Phase III for Pharyngeal Neoplasm.
Pharmaceutical Technology
15 天
Crizotinib by Pfizer for Glioblastoma Multiforme (GBM): Likelihood of Approval
Crizotinib is under clinical development by Pfizer and currently in Phase II for Glioblastoma Multiforme (GBM).
oncnursingnews
14 天
Rate of Cardiovascular Adverse Events, Myocarditis May Be Low in Trials Assessing ICIs
Even with a low rates of cardiovascular adverse events in patients treated with immune checkpoint inhibitors, cancer care ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈